Page 139 - Binder2

Traditional
Feature Platform Approach
Model
Multiple
Disease One autoimmune/inflammatory
Application indication
diseases
Delivery Limited Oral, topical, subcutaneous
Methods
One phase
Lifecycle (e.g., Induction → Maintenance
Coverage → Reinduction
induction)
Repetitive
Manufacturing Streamlined, consistent
customization
Immune Risk with Maintained across
Continuity each switch therapies

Combination Complex, Durable, coordinated
Use risky combinations

This model rewards consistency.
It streamlines manufacturing.
It creates immune continuity across switches and add-ons.
It allows for the possibility of combination durability—
multiple drugs working in concert without compounding
immunogenic risk.

The Cost of Staying Fragmented

If the industry continues to operate reactively, the costs are
clear:

• Higher rates of biologic failure
• More treatment cycles per patient
• Wasted therapies due to immune rejection

137